A microarray-based, integrated approach to identify novel regulators of cancer drug response and apoptosis.

PubWeight™: 0.97‹?› | Rank: Top 15%

🔗 View Article (PMID 12447701)

Published in Oncogene on November 28, 2002

Authors

Arndt Brachat1, Benoit Pierrat, Alexandros Xynos, Karin Brecht, Marjo Simonen, Adrian Brüngger, Jutta Heim

Author Affiliations

1: Oncology Research, Novartis Pharma AG, CH-4002 Basel, Switzerland.

Articles by these authors

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther (2008) 10.35

Prospects for the next anti-Pseudomonas drug. Curr Opin Pharmacol (2009) 2.55

A long ncRNA links copy number variation to a polycomb/trithorax epigenetic switch in FSHD muscular dystrophy. Cell (2012) 2.29

Nogo-A inhibits neurite outgrowth and cell spreading with three discrete regions. J Neurosci (2003) 2.03

Structural basis of ubiquitin recognition by the deubiquitinating protease USP2. Structure (2006) 1.92

Nogo-A-deficient mice reveal strain-dependent differences in axonal regeneration. J Neurosci (2006) 1.89

Biochemical characterization of USP7 reveals post-translational modification sites and structural requirements for substrate processing and subcellular localization. FEBS J (2007) 1.14

Rbfox1 downregulation and altered calpain 3 splicing by FRG1 in a mouse model of Facioscapulohumeral muscular dystrophy (FSHD). PLoS Genet (2013) 1.00

Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt. Biochim Biophys Acta (2011) 0.99

PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo. NMR Biomed (2005) 0.98

New molecules from old classes: revisiting the development of beta-lactams. IDrugs (2009) 0.97

The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells. Biochem Pharmacol (2010) 0.97

Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives. J Pharmacol Exp Ther (2006) 0.94

Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro. Br J Pharmacol (2010) 0.90

Nogo-A expressed in Schwann cells impairs axonal regeneration after peripheral nerve injury. J Cell Biol (2002) 0.89

In vitro and in vivo properties of dihydrophthalazine antifolates, a novel family of antibacterial drugs. Antimicrob Agents Chemother (2009) 0.89

Effect of simvastatin on cholesterol metabolism in C2C12 myotubes and HepG2 cells, and consequences for statin-induced myopathy. Biochem Pharmacol (2009) 0.88

Bioinformatics prediction of overlapping frameshifted translation products in mammalian transcripts. BMC Genomics (2008) 0.87

Second-site NMR screening and linker design. Curr Top Med Chem (2003) 0.84

Hepatocellular toxicity of clopidogrel: mechanisms and risk factors. Free Radic Biol Med (2013) 0.83

FSHD muscular dystrophy region gene 1 binds Suv4-20h1 histone methyltransferase and impairs myogenesis. J Mol Cell Biol (2013) 0.81

Yeast synthetic biology platform generates novel chemical structures as scaffolds for drug discovery. ACS Synth Biol (2014) 0.79

Comparison of variability and sensitivity between nuclear translocation and luciferase reporter gene assays. J Biomol Screen (2009) 0.79

Toxicity of clopidogrel and ticlopidine on human myeloid progenitor cells: importance of metabolites. Toxicology (2012) 0.77

Toxicity of thienopyridines on human neutrophil granulocytes and lymphocytes. Toxicology (2013) 0.75